Curemark CEO Presents Autism Findings At Prestigious Neurobiology Conference At Oxford

Main Category: Autism
Also Included In: Neurology / Neuroscience;  Psychology / Psychiatry
Article Date: 18 Sep 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Curemark, LLC announced that Founder and CEO Dr. Joan Fallon has presented Curemark's most recent findings on autism at the Gordon Conference on Neurobiology and Brain Disorders which took place August 24-29 at Magdalene College in Oxford. This 5-day conference brings together some of the greatest research minds from around the world in the field of neurobiology both from academia and industry.

Dr. Fallon's paper, entitled, "The Role of a Dearth of Amino Acids in the Pathophysiology of Autism" details the groundbreaking discoveries regarding autism and its possible origins. This research is the focus of Curemark's plans for entering into clinical trials.

"It was an incredible honor to be among the most elite scientists in the world looking at the genetics of autism, Alzheimer's, Parkinson's disease and other neurodegenerative conditions." Commented Dr.Fallon, The Gordon Conferences are one of pre-eminent meetings in the world, and I am grateful that Curemark was able to be represented."

Present at the meeting were scientists from MIT, Harvard, Johns Hopkins, Oxford, Cambridge and other prestigious universities from around the world.

Curemark is a drug development company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of key enzymes in children with autism. The company is currently preparing for Clinical Trials.

Curemark